Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience

John M. Bennett, Mary L. Young, Janet W. Andersen, Peter A. Cassileth, Martin S. Tallman, Elisabeth M. Paietta, Peter H. Wiernik, Jacob M. Rowe

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

BACKGROUND. The data base of the Eastern Cooperative Oncology Group (ECOG) provides access to data on a large adult patient population drawn from more than 25 major university institutions and hundreds of participating hospitals. Extensive medical files are maintained at the ECOG Coordinating Center and are updated regularly. METHODS. Data on 1414 eligible patients with acute myeloid leukemia (AML), treated on 6 ECOG protocols during the period 1976-1994, were reviewed to determine the number of long-term survivors (LTS) and to identify factors that predicted LTS. Disease free survival and factors impacting quality of life were examined as well. RESULTS. Of the 1414 patients, 274 survived for ≤23 years and were considered LTS. A logistic regression analysis revealed that factors predicting LTS included age < 55 years, female gender, treatment between 1985 and 1990, white blood cell count < 10,000 cells/mm3, and hemoglobin >10 g/dL. Disease free survival improved with escalating intensity of therapy. Quality-of-life data showed that infections were fairly common. Significant graft-versus-host disease occurred in 6 of 40 patients who received allogeneic bone marrow transplantation and contributed to the deaths of 4 individuals. Information on employment, insurance, social or marital difficulties, and psychosocial issues was more difficult to obtain. CONCLUSIONS. Prognosis in AML is a complex interaction involving the cellular origin of the malignant clone, morphology, and evolving therapeutic strategies. The most recent ECOG studies incorporate these variables and should provide additional insights into factors affecting LTS in patients with AML.

Original languageEnglish (US)
Pages (from-to)2205-2209
Number of pages5
JournalCancer
Volume80
Issue number11 SUPPL.
StatePublished - Dec 1 1997

Fingerprint

Acute Myeloid Leukemia
Survivors
Survival
Disease-Free Survival
Quality of Life
Social Security
Homologous Transplantation
Graft vs Host Disease
Bone Marrow Transplantation
Clone Cells
Logistic Models
Regression Analysis
Databases
Therapeutics
Infection
Population

Keywords

  • Acute myeloid leukemia
  • Long-term survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bennett, J. M., Young, M. L., Andersen, J. W., Cassileth, P. A., Tallman, M. S., Paietta, E. M., ... Rowe, J. M. (1997). Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience. Cancer, 80(11 SUPPL.), 2205-2209.

Long-term survival in acute myeloid leukemia : The Eastern Cooperative Oncology Group experience. / Bennett, John M.; Young, Mary L.; Andersen, Janet W.; Cassileth, Peter A.; Tallman, Martin S.; Paietta, Elisabeth M.; Wiernik, Peter H.; Rowe, Jacob M.

In: Cancer, Vol. 80, No. 11 SUPPL., 01.12.1997, p. 2205-2209.

Research output: Contribution to journalArticle

Bennett, JM, Young, ML, Andersen, JW, Cassileth, PA, Tallman, MS, Paietta, EM, Wiernik, PH & Rowe, JM 1997, 'Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience', Cancer, vol. 80, no. 11 SUPPL., pp. 2205-2209.
Bennett JM, Young ML, Andersen JW, Cassileth PA, Tallman MS, Paietta EM et al. Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience. Cancer. 1997 Dec 1;80(11 SUPPL.):2205-2209.
Bennett, John M. ; Young, Mary L. ; Andersen, Janet W. ; Cassileth, Peter A. ; Tallman, Martin S. ; Paietta, Elisabeth M. ; Wiernik, Peter H. ; Rowe, Jacob M. / Long-term survival in acute myeloid leukemia : The Eastern Cooperative Oncology Group experience. In: Cancer. 1997 ; Vol. 80, No. 11 SUPPL. pp. 2205-2209.
@article{765b2849384c45ff91d8e24532c7907e,
title = "Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience",
abstract = "BACKGROUND. The data base of the Eastern Cooperative Oncology Group (ECOG) provides access to data on a large adult patient population drawn from more than 25 major university institutions and hundreds of participating hospitals. Extensive medical files are maintained at the ECOG Coordinating Center and are updated regularly. METHODS. Data on 1414 eligible patients with acute myeloid leukemia (AML), treated on 6 ECOG protocols during the period 1976-1994, were reviewed to determine the number of long-term survivors (LTS) and to identify factors that predicted LTS. Disease free survival and factors impacting quality of life were examined as well. RESULTS. Of the 1414 patients, 274 survived for ≤23 years and were considered LTS. A logistic regression analysis revealed that factors predicting LTS included age < 55 years, female gender, treatment between 1985 and 1990, white blood cell count < 10,000 cells/mm3, and hemoglobin >10 g/dL. Disease free survival improved with escalating intensity of therapy. Quality-of-life data showed that infections were fairly common. Significant graft-versus-host disease occurred in 6 of 40 patients who received allogeneic bone marrow transplantation and contributed to the deaths of 4 individuals. Information on employment, insurance, social or marital difficulties, and psychosocial issues was more difficult to obtain. CONCLUSIONS. Prognosis in AML is a complex interaction involving the cellular origin of the malignant clone, morphology, and evolving therapeutic strategies. The most recent ECOG studies incorporate these variables and should provide additional insights into factors affecting LTS in patients with AML.",
keywords = "Acute myeloid leukemia, Long-term survival",
author = "Bennett, {John M.} and Young, {Mary L.} and Andersen, {Janet W.} and Cassileth, {Peter A.} and Tallman, {Martin S.} and Paietta, {Elisabeth M.} and Wiernik, {Peter H.} and Rowe, {Jacob M.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "80",
pages = "2205--2209",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11 SUPPL.",

}

TY - JOUR

T1 - Long-term survival in acute myeloid leukemia

T2 - The Eastern Cooperative Oncology Group experience

AU - Bennett, John M.

AU - Young, Mary L.

AU - Andersen, Janet W.

AU - Cassileth, Peter A.

AU - Tallman, Martin S.

AU - Paietta, Elisabeth M.

AU - Wiernik, Peter H.

AU - Rowe, Jacob M.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - BACKGROUND. The data base of the Eastern Cooperative Oncology Group (ECOG) provides access to data on a large adult patient population drawn from more than 25 major university institutions and hundreds of participating hospitals. Extensive medical files are maintained at the ECOG Coordinating Center and are updated regularly. METHODS. Data on 1414 eligible patients with acute myeloid leukemia (AML), treated on 6 ECOG protocols during the period 1976-1994, were reviewed to determine the number of long-term survivors (LTS) and to identify factors that predicted LTS. Disease free survival and factors impacting quality of life were examined as well. RESULTS. Of the 1414 patients, 274 survived for ≤23 years and were considered LTS. A logistic regression analysis revealed that factors predicting LTS included age < 55 years, female gender, treatment between 1985 and 1990, white blood cell count < 10,000 cells/mm3, and hemoglobin >10 g/dL. Disease free survival improved with escalating intensity of therapy. Quality-of-life data showed that infections were fairly common. Significant graft-versus-host disease occurred in 6 of 40 patients who received allogeneic bone marrow transplantation and contributed to the deaths of 4 individuals. Information on employment, insurance, social or marital difficulties, and psychosocial issues was more difficult to obtain. CONCLUSIONS. Prognosis in AML is a complex interaction involving the cellular origin of the malignant clone, morphology, and evolving therapeutic strategies. The most recent ECOG studies incorporate these variables and should provide additional insights into factors affecting LTS in patients with AML.

AB - BACKGROUND. The data base of the Eastern Cooperative Oncology Group (ECOG) provides access to data on a large adult patient population drawn from more than 25 major university institutions and hundreds of participating hospitals. Extensive medical files are maintained at the ECOG Coordinating Center and are updated regularly. METHODS. Data on 1414 eligible patients with acute myeloid leukemia (AML), treated on 6 ECOG protocols during the period 1976-1994, were reviewed to determine the number of long-term survivors (LTS) and to identify factors that predicted LTS. Disease free survival and factors impacting quality of life were examined as well. RESULTS. Of the 1414 patients, 274 survived for ≤23 years and were considered LTS. A logistic regression analysis revealed that factors predicting LTS included age < 55 years, female gender, treatment between 1985 and 1990, white blood cell count < 10,000 cells/mm3, and hemoglobin >10 g/dL. Disease free survival improved with escalating intensity of therapy. Quality-of-life data showed that infections were fairly common. Significant graft-versus-host disease occurred in 6 of 40 patients who received allogeneic bone marrow transplantation and contributed to the deaths of 4 individuals. Information on employment, insurance, social or marital difficulties, and psychosocial issues was more difficult to obtain. CONCLUSIONS. Prognosis in AML is a complex interaction involving the cellular origin of the malignant clone, morphology, and evolving therapeutic strategies. The most recent ECOG studies incorporate these variables and should provide additional insights into factors affecting LTS in patients with AML.

KW - Acute myeloid leukemia

KW - Long-term survival

UR - http://www.scopus.com/inward/record.url?scp=0030722602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030722602&partnerID=8YFLogxK

M3 - Article

C2 - 9395035

AN - SCOPUS:0030722602

VL - 80

SP - 2205

EP - 2209

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11 SUPPL.

ER -